Full Text of PDF (610k)
Article in Japanese
Abstract
Case Report
A case of adalimumab-induced lung injury that developed 3 years after administration
Takafumi Koyauchia Koshi Yokomuraa Misa Sugiyamaa Kei Kanataa Yusuke Amanoa Takafumi Sudab
aDepartment of Respiratory Medicine, Respiratory Disease Center, Seirei Mikatahara Hospital
bSecond Department of Internal Medicine, Hamamatsu University School of Medicine
ABSTRACT
A 63-year-old female with rheumatoid arthritis developed a dry cough and bilateral lower lobe ground-glass opacities with traction bronchiectasis during treatment with methotrexate and adalimumab. Although methotrexate was discontinued, the ground-glass opacities spread. After adalimumab was discontinued, her symptoms and image findings improved. She was diagnosed with adalimumab-induced lung injury that developed 3 years after initial administration of the drug. If lung injury occurs during treatment with adalimumab, adalimumab-induced lung injury should be taken into consideration, while excluding infectious diseases and so on. In addition, we should recognize that adalimumab-induced lung injury can occur even if adalimumab has been used long term.
KEYWORDS
Adalimumab Drug-induced lung injury Rheumatoid arthritis (RA) TNF inhibitors Biological drugs
Received 19 Dec 2017 ／ Accepted 24 Jan 2018
AJRS, 7(2): 114-118, 2018
Copyright © The Japanese Respiratory Society All Rights Reserved.